List of works - Benoit Rousseau

Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy

scientific article published on 6 August 2015

Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.

scientific article

Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives.

scientific article

Alternative Neisseria spp. type IV pilin glycosylation with a glyceramido acetamido trideoxyhexose residue

scientific article

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

scientific article published on 29 November 2019

Are cancer outpatients ready for e-medicine?

scientific article

Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma

scientific article published on 26 February 2019

BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases

scientific article published on 10 June 2019

Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.

scientific article published on 22 April 2016

Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017

scientific article published on 24 July 2017

Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients

scientific article published on 31 May 2019

Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction

scholarly article by Tabassome Simon et al published 6 September 2012 in European Heart Journal

De novo cancer after solid organ transplantation: Epidemiology, prognosis and management

scientific article

Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes

scientific article published on 05 March 2020

First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis

scientific article published on September 2016

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

scientific article published on 11 June 2020

Guidelines and tumor boards are required for solid organ recipients with de novo carcinoma

scientific article published on 19 April 2019

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

scientific article published on 12 March 2020

Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond

scientific article published on 01 February 2020

Immune Therapy for Liver Cancers

scientific article published on 27 December 2019

Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.

scientific article

Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma

scientific article published on 11 September 2018

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

scientific article

Medical management of cholangiocarcinomas in 2015

scientific article published on 24 February 2016

NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas

scientific article published on 14 June 2019

Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?

scientific article

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group

scientific article published on 05 December 2019

Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma

scientific article published on 20 November 2018

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.

scientific article published on 4 April 2017

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.

scientific article

Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency

scientific article published on 23 March 2017

Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort

scientific article published on 21 August 2019

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations

scientific article published on 01 March 2019

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.

scientific article published on 25 October 2016

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.

scientific article published on 30 June 2016

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs

scientific article published on 13 October 2015

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

scientific article published on 09 December 2019

Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma

scientific article published on June 2016

Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.

scientific article published in May 2017

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

scientific article published on 29 October 2011

Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs

scientific article

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.

scientific article published on 8 September 2017

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

scientific article published on 03 December 2020

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas

scientific article published on 13 February 2017

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.

scientific article

What Do Older Adults Know About Their Cancer Diagnosis and Treatment? The ELCAPA-08 Cohort Study.

scientific article published in June 2016

[A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research]

scientific article published on 12 April 2019

[Genealogy of lymph node and visceral metastases in colorectal cancer: "sisters" or "cousins"?]

scientific article published on 24 August 2018

[Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden]

scientific article published on 11 January 2019

[Immunotherapies and targeted therapies in medical oncology]

scientific article published on 01 January 2014

[Internet as a tool in oncology: critical analysis]

scientific article published on 01 October 2010

List of works by Benoit Rousseau

Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy

Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.

Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives.

Alternative Neisseria spp. type IV pilin glycosylation with a glyceramido acetamido trideoxyhexose residue

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Are cancer outpatients ready for e-medicine?

Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma

BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases

Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.

Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017

Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients

Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction

De novo cancer after solid organ transplantation: Epidemiology, prognosis and management

Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes

First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

Guidelines and tumor boards are required for solid organ recipients with de novo carcinoma

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond

Immune Therapy for Liver Cancers

Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.

Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

Medical management of cholangiocarcinomas in 2015

NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas

Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group

Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.

Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency

Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma

Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.

What Do Older Adults Know About Their Cancer Diagnosis and Treatment? The ELCAPA-08 Cohort Study.

[A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research]

[Genealogy of lymph node and visceral metastases in colorectal cancer: "sisters" or "cousins"?]

[Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden]

[Immunotherapies and targeted therapies in medical oncology]

[Internet as a tool in oncology: critical analysis]